KR102630010B1 - Tnf의 억제제로서 유용한 트리시클릭 헤테로시클릭 화합물 - Google Patents

Tnf의 억제제로서 유용한 트리시클릭 헤테로시클릭 화합물 Download PDF

Info

Publication number
KR102630010B1
KR102630010B1 KR1020177029450A KR20177029450A KR102630010B1 KR 102630010 B1 KR102630010 B1 KR 102630010B1 KR 1020177029450 A KR1020177029450 A KR 1020177029450A KR 20177029450 A KR20177029450 A KR 20177029450A KR 102630010 B1 KR102630010 B1 KR 102630010B1
Authority
KR
South Korea
Prior art keywords
phenyl
imidazo
difluoromethoxy
tetrahydropyrido
pyridazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177029450A
Other languages
English (en)
Korean (ko)
Other versions
KR20170129811A (ko
Inventor
스티븐 티. 로블레스키
그레고리 디. 브라운
수췬 린
징우 두안
종후이 루
티.지. 무랄리 다르
하이-윤 샤오
앤드류 제이. 테벤
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20170129811A publication Critical patent/KR20170129811A/ko
Application granted granted Critical
Publication of KR102630010B1 publication Critical patent/KR102630010B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020177029450A 2015-03-18 2016-03-17 Tnf의 억제제로서 유용한 트리시클릭 헤테로시클릭 화합물 Active KR102630010B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562134779P 2015-03-18 2015-03-18
US62/134,779 2015-03-18
PCT/US2016/022738 WO2016149437A1 (en) 2015-03-18 2016-03-17 Tricyclic heterocyclic compounds useful as inhibitors of tnf

Publications (2)

Publication Number Publication Date
KR20170129811A KR20170129811A (ko) 2017-11-27
KR102630010B1 true KR102630010B1 (ko) 2024-01-25

Family

ID=55640933

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177029450A Active KR102630010B1 (ko) 2015-03-18 2016-03-17 Tnf의 억제제로서 유용한 트리시클릭 헤테로시클릭 화합물

Country Status (14)

Country Link
US (1) US10308652B2 (https=)
EP (1) EP3271361B1 (https=)
JP (1) JP6793658B2 (https=)
KR (1) KR102630010B1 (https=)
CN (1) CN107635992B (https=)
AU (1) AU2016233289A1 (https=)
BR (1) BR112017019731A2 (https=)
CA (1) CA2982446A1 (https=)
EA (1) EA032314B1 (https=)
ES (1) ES2797685T3 (https=)
IL (1) IL254520A0 (https=)
MX (1) MX2017011433A (https=)
SG (1) SG11201707471RA (https=)
WO (1) WO2016149437A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107635993B (zh) 2015-03-18 2020-05-22 百时美施贵宝公司 取代的三环杂环化合物
WO2016149439A1 (en) 2015-03-18 2016-09-22 Bristol-Myers Squibb Company Heterocyclic compounds useful as inhibitors of tnf
EP3288939A1 (en) 2015-04-17 2018-03-07 AbbVie Inc. Tricyclic modulators of tnf signaling
WO2016168633A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Indazolones as modulators of tnf signaling
US9879016B2 (en) 2015-04-17 2018-01-30 Abbvie Inc. Indazolones as modulators of TNF signaling
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
BR112018001980A2 (pt) 2015-08-03 2018-09-18 Bristol Myers Squibb Co compostos cíclicos úteis como moduladores de tnf alfa
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
CN110461842A (zh) 2017-03-15 2019-11-15 Ucb生物制药私人有限公司 作为tnf活性调节剂的稠合五环咪唑衍生物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014009295A1 (en) 2012-07-13 2014-01-16 Ucb Pharma S.A. Imidazopyridine derivatives as modulators of tnf activity

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391806A (en) * 1982-07-12 1983-07-05 The Dow Chemical Company Substituted tetrahydropyridazino-(1,6-A)benzimidazoles and use as bronchodilators
CA2281927C (en) 1997-02-25 2004-01-27 Christopher J. Michejda Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase
ATE311385T1 (de) * 1999-10-27 2005-12-15 Novartis Pharma Gmbh Thiazol und imidazo(4,5-b)pyridin verbindungen und ihre verwendung als pharmazeutika
JPWO2003064422A1 (ja) 2002-01-31 2005-05-26 第一製薬株式会社 イミダゾ［１，２−ａ］ピリジン誘導体
AU2003298839A1 (en) 2002-12-03 2004-06-23 Isis Pharmaceuticals, Inc. Benzimidazoles and analogs thereof as antivirals
US20050124638A1 (en) 2003-12-08 2005-06-09 Swayze Eric E. Benzimidazoles and analogs thereof as antivirals
EP2209785A1 (en) 2007-10-05 2010-07-28 S*BIO Pte Ltd 2-morpholinylpurines as inhibitors of pi3k
CN101717397B (zh) 2008-10-09 2012-11-28 中国科学院上海药物研究所 一类取代吡啶并[2',1':2,3]咪唑并[4,5-c]异喹啉酮类化合物及其合成方法和用途,以及包含该类化合物的药物组合物
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
WO2012148550A1 (en) 2011-02-25 2012-11-01 Myrexis, Inc. Prodrugs of therapeutic compounds
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
US9550737B2 (en) 2012-06-11 2017-01-24 Ucb Biopharma Sprl TNF -α modulating benzimidazoles
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
MX2015005375A (es) * 2012-11-07 2015-07-21 Hoffmann La Roche Compuestos de triazolo.
ES2529865B8 (es) * 2013-07-25 2016-01-22 Fundación Para La Investigación Biomédica Del Hospital Universitario La Paz (Fibhulp) USO DE COMPUESTOS DERIVADOS DE SALES DE PIRIDAZINO[1',6':1,2]PIRIDO[3,4-b]INDOLINIO COMO AGENTES ANTIINFLAMATORIOS
GB201321741D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321738D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
RU2685234C1 (ru) 2013-12-09 2019-04-17 Юсб Байофарма Спрл Конденсированные бициклические гетероароматические производные в качестве модуляторов активности tnf
US9920052B2 (en) 2013-12-09 2018-03-20 Ucb Biopharma Sprl Imidazopyridine derivatives as modulators of TNF activity
GB201321743D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321742D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321744D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321745D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321735D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321739D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
MX388321B (es) 2014-10-06 2025-03-19 Signal Pharm Llc Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
CN107635993B (zh) 2015-03-18 2020-05-22 百时美施贵宝公司 取代的三环杂环化合物
WO2016149439A1 (en) 2015-03-18 2016-09-22 Bristol-Myers Squibb Company Heterocyclic compounds useful as inhibitors of tnf
EP3288939A1 (en) * 2015-04-17 2018-03-07 AbbVie Inc. Tricyclic modulators of tnf signaling
US20180155344A1 (en) * 2015-05-04 2018-06-07 Actelion Pharmaceuticals Ltd Tricyclic piperidine compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014009295A1 (en) 2012-07-13 2014-01-16 Ucb Pharma S.A. Imidazopyridine derivatives as modulators of tnf activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Vikas Chaudhary 등, RCS advances, 2015, 제5권, 페이지 26051~26060

Also Published As

Publication number Publication date
AU2016233289A1 (en) 2017-11-09
EA032314B1 (ru) 2019-05-31
US20180111937A1 (en) 2018-04-26
EP3271361B1 (en) 2020-04-22
CA2982446A1 (en) 2016-09-22
IL254520A0 (en) 2017-11-30
WO2016149437A1 (en) 2016-09-22
CN107635992A (zh) 2018-01-26
JP2018508554A (ja) 2018-03-29
CN107635992B (zh) 2020-05-22
ES2797685T3 (es) 2020-12-03
US10308652B2 (en) 2019-06-04
KR20170129811A (ko) 2017-11-27
BR112017019731A2 (pt) 2018-05-22
SG11201707471RA (en) 2017-10-30
EA201792025A1 (ru) 2018-01-31
EP3271361A1 (en) 2018-01-24
MX2017011433A (es) 2017-11-10
JP6793658B2 (ja) 2020-12-02

Similar Documents

Publication Publication Date Title
KR102630010B1 (ko) Tnf의 억제제로서 유용한 트리시클릭 헤테로시클릭 화합물
JP7299382B2 (ja) Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体
KR102442235B1 (ko) 융합된 펜타시클릭 이미다졸 유도체
KR102696304B1 (ko) Tnf의 억제제로서 유용한 헤테로시클릭 화합물
KR102654709B1 (ko) 치환된 트리시클릭 헤테로시클릭 화합물
EP3596078B1 (en) Fused pentacyclic imidazole derivatives as modulators of tnf activity
JP2021193099A (ja) 置換４−アザインドール及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用
CA2985547A1 (en) Substituted tetrahydroquinolinone compounds as ror gamma modulators
JP6811233B2 (ja) Ｔｎｆアルファの修飾因子として有用な環状化合物
JP2011510004A (ja) タンパク質キナーゼ阻害剤及びその使用
JP2019512534A (ja) Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体
AU2022369094A1 (en) Tricyclic gpr65 modulators
AU2019424628B2 (en) 1,2,3,4-tetrahydroquinoxaline derivative, preparation method therefor and application thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20171013

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210316

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230403

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20231113

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240123

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240123

End annual number: 3

Start annual number: 1

PG1601 Publication of registration